EF Hutton analyst Michael King initiated coverage of Agenus with a Buy rating and $8.30 price target and nominated it as his top pick, arguing that the company has “one of the industry’s most productive portfolios of I/O assets,” but is “not getting the credit it deserves.” Many of its antibody peers either have smaller pipelines or less advanced clinical candidates, according to King, who sees Agenus as likely to create significant value as its “prodigious pipeline blossoms over the next 12-24 months.”
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGEN:
Source
